BACKGROUND: S-1OOB, a protein of astroglial cells, is described as a marker for @entity528 . Reliable outcome prediction from severe @entity542 is still unresolved. Clinical scores such as the Glasgow @entity772 Scale score (GCS) and diagnostic scores such as the Marshall Computed Tomographic Classification are well established and investigated, but there are still some concerns about these tools. The aim of this study was to investigate the predictive value of the initial serum level of @entity4483 compared with the predictive value of the GCS score and the Marshall Computed Tomographic Classification to outcome after severe @entity542 . METHODS: Forty-four @entity1 with severe @entity542 (GCS score < 9) were included. Blood samples were drawn within 1 to 6 hours of injury. After a period of 11 months, their outcome was correlated by using the Glasgow Outcome Scale. @entity1 with an @entity4483 serum level above 2 microg/L, a GCS score between 3 and 5, and a computed tomographic scan in the categories 4 to 6 are predicted to have an unfavorable outcome. The predictive values of these tools were calculated according to these definitions. RESULTS: The protein @entity4483 had with 17% the lowest total misclassification rate. When compared with the GCS score and Marshall Computed Tomographic Classification the @entity4483 serum level calculated on admission had the highest positive predictive value (87%) and negative predictive value (77%). CONCLUSION: The serum level of @entity4483 calculated within 1 to 6 hours of a severe @entity542 is a useful additional outcome predictor.

Comparison of clinical, radiologic, and serum marker as prognostic factors after severe XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity542 :: ('MESH:D006259', 'Disease') :: ['head injury'] @entity4483 :: ('6285', 'Gene') :: ['S-100B'] @entity772 :: ('MESH:D003128', 'Disease') :: ['Coma'] @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal damage']
@entity542 :: (MESH:D006259,Disease) :: ['head injury']
